New England Journal of Medicine· 2013Q1

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White, Christopher P. Cannon, Simon Heller, Steven E. Nissen et al.

2,525citations
Q1SCImago
2013year

Short summary

In patients with type 2 diabetes and recent acute coronary syndrome, the DPP-4 inhibitor alogliptin did not increase the risk of major adverse cardiovascular events compared to placebo.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine